Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of: Efficiencies in donor selection to reduce uncertainties about HLA matching and improve patient outcomes HLA complexity in cell source selection How machine…
Watch this on-demand webinar for an in-depth discussion on these questions and more. You’ll walk away with insights on navigating the scalability of donor starting material as the allogeneic cell therapy industry grows. PANELISTS Abby Waters, PhD Senior Manager, Solutions Owner Be The Match BioTherapies Dean A. Lee, MD, PhD Physician, Hematology and Oncology Director…
Navigating international regulations for cellular starting material is complex. This is particularly true because the rapid advancement of the industry sometimes precedes regulatory guidance. When you’re procuring cellular starting material or distributing a cell or gene therapy product across international borders, you must consider the country or regional requirements at play and where they diverge.…
Learn why cord blood may be an excellent starting material for your therapy Cord blood has been used to provide life-saving treatments to patients for decades, but its full potential has not yet been tapped. During this hour long on-demand webinar, our panelists discuss: Why it’s essential to have a good understanding of critical starting…
To ensure safe, high-quality Advanced Therapy Medicinal Products (ATMPs) are delivered to patients, procurement activities must be standardized when possible. Standardization also supports efficiency and reduces the risk for error while meeting regulatory and accreditation requirements. Download the UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture for insights…
A joint venture between the European Society of Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), the CAR-T Cell Handbook offers clinical care applications for health care professionals in the EU that treat patients with CAR-T cell therapies. Download the guide for insights into many aspects of CAR-T cell therapies including: The…
Off-the-shelf cord blood units (CBUs) are a rich source of cells for use in the development of allogeneic cell and gene therapies. However, CBUs with the characteristics you need may be spread across multiple cord blood banks. Understanding which cord blood banks have the CBUs that meet your requirements is a challenge. And qualifying and…
Considerations for developing scalable and efficient collection network processes The decisions you make when selecting apheresis centers to collect source material for your cell or gene therapy impact your ability to efficiently scale your processes. When your processes and protocols differ from those at an apheresis center, delays can occur. Following best practices can help.…
The ONE Forum 2021: On-demand session As cell and gene therapies continue to progress at a rapid pace, apheresis and collection centers face the challenges of keeping up with demand, while maintaining high-quality levels. This session focuses on capability and capacity considerations to support these emerging therapies, standardization strategies and solutions that can bring efficiencies…
